Chengda Pharmaceuticals Co (SZSE:301201) Cyclically Adjusted FCF per Share: ¥-0.26 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301201 Chengda Pharmaceuticals Co Ltd SZSE:301201
78 GF Score
Price ¥27.74
GF Value ¥30.45
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Chengda Pharmaceuticals Co Cyclically Adjusted FCF per Share?

Chengda Pharmaceuticals Co SZSE:301201 +2.44% 78 Cyclically Adjusted FCF per Share is ¥-0.26 as of Mar. 2026. GuruFocus rates SZSE:301201 with a GF Score™ of 78/100 and a GF Value™ of ¥30.45 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Chengda Pharmaceuticals Co's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2025 was ¥-0.231. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥-0.26 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-02), Chengda Pharmaceuticals Co's current stock price is ¥ 27.74. Chengda Pharmaceuticals Co's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2025 was ¥-0.26. Chengda Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF of today is .

During the past 12 years, the highest Cyclically Adjusted Price-to-FCF of Chengda Pharmaceuticals Co was 45.13. The lowest was 31.20. And the median was 37.73.


Chengda Pharmaceuticals Co  (SZSE:301201) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 12 years, the highest Cyclically Adjusted Price-to-FCF of Chengda Pharmaceuticals Co was 45.13. The lowest was 31.20. And the median was 37.73.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Chengda Pharmaceuticals Co Cyclically Adjusted FCF per Share Related Terms


Chengda Pharmaceuticals Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Chengda Pharmaceuticals Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengda Pharmaceuticals Co Cyclically Adjusted FCF per Share Chart

Chengda Pharmaceuticals Co Annual Data
Trend Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.55 -0.28 -0.26

Chengda Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.26 0.00

SZSE:301201 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chengda Pharmaceuticals Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Chengda Pharmaceuticals Co's Cyclically Adjusted Price-to-FCF falls into.


SZSE:301201
78GF Score
Chengda Pharmaceuticals Co Ltd SZSE:301201
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengda Pharmaceuticals Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Chengda Pharmaceuticals Co's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-0.231/115.8323*115.8323
=-0.231

Current CPI (Dec. 2025) = 115.8323.

Chengda Pharmaceuticals Co Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201012 0.075 89.289 0.097
201712 -0.003 104.500 -0.003
201812 0.210 106.500 0.228
201912 0.155 111.200 0.161
202012 0.562 111.500 0.584
202112 -0.479 113.108 -0.491
202212 -1.043 115.116 -1.049
202312 -0.211 114.781 -0.213
202412 -1.696 114.893 -1.710
202512 -0.231 115.832 -0.231

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ¥-0.26 mean?
Chengda Pharmaceuticals Co (SZSE:301201) has a Cyclically Adjusted FCF per Share of ¥-0.26 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Chengda Pharmaceuticals Co and its competitors.
Is Chengda Pharmaceuticals Co's Cyclically Adjusted FCF per Share too high?
Chengda Pharmaceuticals Co's current Cyclically Adjusted FCF per Share is ¥-0.26. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's Cyclically Adjusted FCF per Share compare to ZTS?
Chengda Pharmaceuticals Co's Cyclically Adjusted FCF per Share of ¥-0.26 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Chengda Pharmaceuticals Co and its competitors. Chengda Pharmaceuticals Co's current Cyclically Adjusted FCF per Share is ¥-0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Fairly Valued. The stock's GF Value™ is ¥30.45, compared to a current price of ¥27.74 — trading 8.9% below its estimated fair value. The current Cyclically Adjusted FCF per Share is ¥-0.26. Chengda Pharmaceuticals Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current Cyclically Adjusted FCF per Share is ¥-0.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?

Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥27.74 is trading 8.9% below its estimated GF Value™ of ¥30.45. GuruFocus considers Chengda Pharmaceuticals Co to be Fairly Valued.

Key valuation signals for SZSE:301201:

  • Cyclically Adjusted FCF per Share: ¥-0.26
  • GF Value™: ¥30.45 vs. price of ¥27.74 (8.9% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chengda Pharmaceuticals Co Business Description

Address 36 Huanghe Road, Huimin Street, Jiashan County, Zhejiang Province, Jiaxing, CHN, 314100
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
78GF Score

Get the complete analysis for SZSE:301201

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.74
Price
¥30.45
GF Value